Actively Recruiting
A Retrospective Study on Donor Leukocyte Telomere Length and Prognosis in Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
Led by Zhejiang University · Updated on 2023-10-10
2500
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) to understand how the length of donor leukocyte telomeres relates to patient outcomes. This observational study includes patients aged 5 to 90 years who achieved complete remission and full donor engraftment after transplantation. The study was conducted at Zhejiang University schools of medicine and complies with ethical standards. The study involves no interventions or treatments; it is an observational analysis. Donors' leukocyte telomere lengths were measured from blood samples collected before receiving granulocyte colony-stimulating factor (G-CSF) mobilization. Patients and donors were grouped by donor age (40 years or older versus younger than 40) to observe differences. Participants are followed after transplantation with assessments including overall survival up to 60 months, relapse-free survival, and cumulative incidence of relapse. Researchers evaluate survival outcomes from the date of transplant until death, relapse, or end of follow-up. The study collects clinical data and donor telomere measurements to analyze prognosis in acute leukemia patients post-transplant.
CONDITIONS
Brief Title
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 5 years or older
- First allogeneic hematopoietic stem cell transplant from matched related, unrelated, or haploidentical donors
- Achieved complete remission after allo-HSCT
- Donor blood sample collected before granulocyte colony-stimulating factor mobilization
You will not qualify if you...
- Diagnoses other than acute leukemia, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia
- Failure to achieve engraftment with full donor chimerism after allo-HSCT
- Inability to extract DNA for telomere length analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 60 months
Participants are observed following their allogeneic hematopoietic stem cell transplantation to assess survival and relapse outcomes.
Regular follow-up visits according to routine clinical care
Trial Site Locations
Total: 1 location
1
Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University
Hangzhou, Zhejiang, China
Actively Recruiting
Research Team
H
He Huang, PhD&MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here